e-learning
resources
Vienna 2009
Monday, 14.09.2009
New bronchodilators
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study
versus
placebo and tiotropium
J. Lötvall, B. G. Cosio, A. Iqbal, J. Swales, R. Owen, B. Kramer, M. Higgins (Göteborg, Sweden; Palma de Mallorca, Spain; Horsham, United Kingdom; East Hanover, United States Of America)
Source:
Annual Congress 2009 - New bronchodilators
Session:
New bronchodilators
Session type:
Thematic Poster Session
Number:
2029
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Lötvall, B. G. Cosio, A. Iqbal, J. Swales, R. Owen, B. Kramer, M. Higgins (Göteborg, Sweden; Palma de Mallorca, Spain; Horsham, United Kingdom; East Hanover, United States Of America). Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study
versus
placebo and tiotropium. Eur Respir J 2009; 34: Suppl. 53, 2029
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation
vs
placebo and tiotropium
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation
vs
placebo (pbo) and formoterol (for)
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009
48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison
Source: Eur Respir J 2011; 37: 273
Year: 2011
LATE-BREAKING ABSTRACT: Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: The SHINE study
Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases
Year: 2012
Efficacy and safety of indacaterol 150 μg once-daily in COPD: a 12-week study
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009
LATE-BREAKING ABSTRACT: Once-daily QVA149 significantly improves lung function and symptoms compared to twice-daily fluticasone/salmeterol in COPD patients: The ILLUMINATE study
Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments
Year: 2012
Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009
Once-daily NVA237 reduces exacerbations and improves symptoms in COPD patients: A pooled analysis of the GLOW1 and GLOW2 studies
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010
Cardiovascular safety of qva149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 665s
Year: 2006
Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
NVA237 once daily provides rapid, clinically meaningful and sustained 24-h bronchodilation in patients with COPD: The GLOW1 trial
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studies
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
NVA237 once daily reduces the percentage of patients with exacerbations of COPD and associated hospitalizations: The GLOW1 trial
Source: Annual Congress 2011 - New treatments for airway disease
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept